A 59-year-old female was admitted to Tsukuba University Hospital and diagnosed as IgA-A multiple myeloma (stage IIIA). No cardiovascular disorder with the exception of minor ischemic changes in ECG was revealed before treatment. Recombinant human a-interferon (IFN) at a dose of 3 million units combined with melphalan and prednisolone was administrated. Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF). Treatment with diuretics and catecholamine products showed almost complete recovery from CHF in 3 weeks. An adverse reaction to IFN was strongly suspected as the cause of CHF. (Internal Medicine 31: 936-940, 1992) 
Introduction
Interferon (IFN), primarily found as an anti-viral agent, has also been demonstrated to have anti-tumor activity in vitro and in vivo (1) (2) (3) (4) . Therapeutical effects of IFN on renal cell carcinoma, multiple myeloma, hairy-cell leukemia, chronic myelogenous leukemia, and non-Hodgkin's lymphoma have been documented (5) (6) (7) (8) (9) . Adverse reactions to IFN include fever, which frequently appears, nausea, vomiting, fatigue, leukocy topenia, and thrombocytopenia (10) (11) (12) (13) (14) (15) . Reactions involving the circulatory system are not rare (13) (14) (15) (16) although the incidence of congestive heart failure (CHF) during IFN therapy is very low. We report here a patient with multiple myeloma in whom CHF occurred following the first administration of recombinant human ar-IFN. Adverse reaction of the myocardium and/or cardio vascular system to ar-IFN inducing CHF is reviewed and the relation of the present case to those in the literature is discussed.
Case Report
A 59-year-old female was admitted to Tsukuba Uni versity Hospital in February 1989, for the treatment of multiple myeloma. The diagnosis of multiple myeloma had been made in October 1988, and she had been treated with a combination chemotherapy of melphalan, prednisolone (PSL), and methotrexate, at another clinic. She had no past history of cardio-pulmonary disorders. On admission to our hospital, heart rate was 76/min without irregularity and blood pressure was 160/78mmHg. She was slightly anemic, however, no heart murmur ausculated. Neither hepatosplenomegaly nor any symptoms of CHF were found. Hematological examinations revealed a hemoglobin level of 8.7 g/dl, leukocyte 1,000/[A, and platelet 37,000//i. Bone marrow aspiration from the sternum revealed myeloma cells with distinct nucleoli in 81.2% of the nucleated cells. Erythrocyte sedimentation rate was 152 mm/h, and total protein 9.3g/dl, serum albumin 3.1g/dl, serum IgA 4,710mg/dl (remarkably increased), IgM 76mg/dl (at the lower limit of normal), and IgG 353mg/dl (less than the normal value). Blood urea nitrogen was 7.0mg/dl, the serum creatinine 0.9 mg/dl, and creatinine clearance 36.6ml/min. Blood chemistry for liver function within showing inverted T waves in V2, V3 with increased; the flat T wave in V4 became negative. ST-segment depression in V4-V^ were nor malized. C) ECG on March 12 (25 days after CHF) shows that inverted T waves in V4 returned to flat waves but were unaltered in V2, V3. abnormalities in the electro-cardiogram (ECG) (inverted T waves in V2, V3, flat T waves in V4, V5 and inverted U waves with ST-segment depression in V4-V6) were found on admission (Fig. 1) . Chest X-ray showed no abnormalities. Left ventricular hypertrophy was most likely, however, myocardial ischemia could not be ex cluded. Before chemotherapy, ultrasonic cardiography (UCG) was not performed. Based on her good performance status (grade 1) and the fact that the abnormalities of the cardio-and renal-functions were minor, we considered her to be tolerant of ar-IFN treatment combined with melphalan and prednisolone. At 8 PM on February 15, 1989, 5 hours after the first intramuscular injection of 3 million units of IFN, 10 hours after the oral administration of 2 mg melphalan and 10mg PSL, and she vomited without any remarkable changes in vital signs. Thereafter, her body temperature gradually rose to 39°C by the following morning. She again vomited, 16 hours after the first administration of IFN, and her consciousness level declined. Blood gas analysis showed hypoxemia with a PaO2 of 42.8mmHg. Based on chest X-ray findings showing pulmonary congestion , increased central venous pressure, and reduced fractional shortening and wall motion on UCG, a diagnosis of CHF was made. On ECG, inverted T waves in V2, V3 increased in magnitude and T wave in V4 became inverted. ST-segment de pressions in V4-V6 were normalized (Fig. 1) . Neither a fluid imbalance nor acute cardiovascular disorder was found. As we suspected an adverse reaction to IFN as a cause of CHF, the administration of IFN was suspended. Chemotherapy consisting of melphalan and PSL was continued thereafter. Treatment with diuretics, cardiac glycoside and catecholamine products resulted in a remarkable improvement of cardiopulmonary function (Fig. 2) . Inverted T waves in V4 returned to flat but unaltered waves in V2, V3 (Fig. 1) , however, she re covered from CHF almost completely in approximately Fig. 2 . Ultrasonic cardiography, short-axis parasternal echo cardiography, at the level of papillary muscles during the diastolic phase (left) and systolic phase (right) on February 22 (A) (6 days after CHF). Fractional shortening was reduced (23%) and generalized hypokinesis of left ventricule was found. Echocardiography on April 3 (B) (47 days after CHF) showed normalized fractional shortening (33%) and improved wall motions.
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Medicine Vol. 31, No. 7 (July 1992) 3 weeks. During the recovery phase from CHF, her renal function was gradually lowered. Plasmaphereses were performed to alleviate hyperviscosity, and subsequently serum creatinine was lowered and creatinine clearance was slightly improved (Fig. 3) . Although chemotherapy consisting of melphalan and PSL was continued, serum M component was not normalized and the serum calcium concentration was gradually elevated. In May, her con sciousness level gradually declined again. Serum levels of IgA, calcium, and creatinine were not lowered, while several plasmaphereses and a hemodialysis were per- Fig. 4 . Microscopic findings of the heart at autopsy. Neither myocardial necrosis, infiltration of myeloma cells nor deposition of amyloid was found in the myocardium (HE, X140).
formed. At this time, the myeloma itself was refractory to chemotherapy and systemic candidiasis developed. She died of candidiasis and hemorrhagic complication on May 30, 1989 (Fig. 3) . Autopsy revealed infiltration of myeloma cells not only to the bone marrow of thoracic and lumbar vertebras, sternum, and ribs, but also to the liver, spleen, kidneys, adrenal glands, stomach, pancreas, and lungs. No deposition of amyloid was found in the kidneys, but so-called "myeloma kidneys" (deposition of protein-like substances in tubules) were demonstrated. Systemic lesions of candidiasis were also found. Autopsy revealed neither infarction, in filtration of myeloma cells, nor deposition of amyloid in the myocardium (Fig. 4) . Discussion
Adverse reactions frequently seen with IFN treatment include fever, nausea, vomiting, fatigue, leukocytopenia, and thrombocytopenia, most of which are reversible and tolerable (10) (11) (12) (13) (14) (15) . However, there have been a few reports of serious adverse reactions to IFN. Adverse reactions other than CHF related to the circulatory system which are observed during or immediately after the administration of IFN include hypotension, sudden death, and acute myocardial infarction (13) . Supraven tricular or ventricular arrhythmias, and dilated cardi omyopathy have also been reported (17) . CHF reported in relation to the treatment with ar-IFN are rare (16-22) , y-IFN very rare (23, 24), and no reports with /3-IFN in 
